Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, integrated biopharmaceutical company Alkermes
With that in mind, let's take a closer look at Alkermes and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Dublin (1987)|
|Market Cap||$2.3 billion|
|Trailing-12-Month Revenue||$390.0 million|
|Management||Chairman/CEO Richard Pops
CFO James Frates
|Return on Equity (average, past 3 years)||(13%)|
|Cash/Debt||$190.5 million / $445.0 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 248 members who have rated Alkermes believe the stock will outperform the S&P 500 going forward.
These guys use technology to improve existing drugs, and make them less burdensome for patients to take. Plus, they're inventing a lot of new ones themselves. I think 2012 could be the breakout year for Alkermes, as the company now has five drugs on the market and, next year, they expect to see double-digit revenue growth. ... Plus, Alkermes has a hefty pipeline ... that's what matters ... where the company keeps on developing better drugs in areas they know well. This company is the opposite of the big, old-line pharma companies that seem to have hit the wall, or fallen off the cliff ... the patent cliff, that is.
If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Alkermes may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
More from The Motley Fool
The Clear Reason Alkermes Plc's Shares Jumped by as Much as 12%
Some belt-tightening packed a punch in an otherwise mixed third-quarter earnings report.
Alkermes Reports Mixed Results, Updates Guidance
Revenue growth of 21% wasn't enough to meet expectations, but expense control helped to save the day.
3 Biotech Stocks for Enterprising Investors
Looking for a few biotech stocks that have upside potential? Here's why our investors think you should check out Edge Therapeutics, Aratana Therapeutics, and Alkermes.